ENSC:NASDAQEnsysce Biosciences, Inc. Analysis

Ensysce Biosciences (ENSC) trades at $0.278, well below its 52‑week low of $0.23 and far beneath the analyst target of $16.45, indicating a massive implied upside. The 20‑day SMA (0.281) sits just above the current price while the 50‑day (0.363) and 200‑day (1.124) SMAs are markedly higher, confirming a short‑term bearish bias. The RSI of 44 suggests neutral momentum, and the MACD histogram is modestly positive (+0.0057) despite a bearish overall trend and a beta of 1.06. Volatility is extreme at 110% over 30 days and the stock has suffered a historical max drawdown of over 90%, highlighting the high risk profile. Fundamentally, the company reports negative revenue growth (-27%), negative margins across the board, zero EBITDA, and a trailing EPS of -3.11, resulting in a meaningless PE and a PB of -7.5.
Recent material news reveals an IRB approval for the PF614‑MPAR candidate and an expanded patent estate protecting the MPAR platform through 2042, which could catalyze future value if clinical milestones are met. However, operating cash flow remains deeply negative (‑$9.6 M) and free cash flow is also heavily negative, underscoring cash‑burn concerns. The market cap is only $4.3 M with increasing volume, but liquidity remains thin. Overall, the stock presents a speculative play: the technical setup is bearish, fundamentals are distressed, yet the pipeline and patent protection offer a long‑run upside narrative.